RENASCIENCE INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 347 JPY | 0.00% |
|
-0.57% | -20.05% |
Valuation
| Fiscal Period: Marzo | 2022 | 2023 | 2024 |
|---|---|---|---|
| Capitalization 1 | 5,669 | 5,695 | 4,843 |
| Enterprise Value (EV) 1 | 3,482 | 3,792 | 3,173 |
| P/E ratio | -20 x | -17 x | -18.8 x |
| Yield | - | - | - |
| Capitalization / Revenue | 40.8 x | 56.9 x | 25 x |
| EV / Revenue | 25.1 x | 37.9 x | 16.4 x |
| EV / EBITDA | -16,742,395 x | -11,386,912 x | -12,642,063 x |
| EV / FCF | -23,216,121 x | -23,736,098 x | -23,246,577 x |
| FCF Yield | -0% | -0% | -0% |
| Price to Book | 2.57 x | 3.05 x | 3.02 x |
| Nbr of stocks (in thousands) | 12,712 | 12,712 | 12,712 |
| Reference price 2 | 446.0 | 448.0 | 381.0 |
| Announcement Date | 6/30/22 | 6/30/23 | 6/28/24 |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Marzo | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Net sales 1 | 72 | 209 | 139 | 100 | 194 |
| EBITDA | - | - | -208 | -333 | -251 |
| EBIT 1 | -183 | -85 | -211 | -334 | -252 |
| Operating Margin | -254.17% | -40.67% | -151.8% | -334% | -129.9% |
| Earnings before Tax (EBT) 1 | -184 | -100 | -253 | -334 | -257 |
| Net income 1 | -184 | -100 | -254 | -335 | -258 |
| Net margin | -255.56% | -47.85% | -182.73% | -335% | -132.99% |
| EPS 2 | -18.74 | -10.18 | -22.30 | -26.35 | -20.30 |
| Free Cash Flow | - | - | -150 | -159.8 | -136.5 |
| FCF margin | - | - | -107.91% | -159.75% | -70.36% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 8/18/21 | 8/18/21 | 6/30/22 | 6/30/23 | 6/28/24 |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: Marzo | 2022 S1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 S1 | 2023 Q3 | 2024 Q1 | 2024 S1 | 2024 Q3 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales | 31 | 35 | 73 | 20 | 20 | 10 | 93 | 120 | - |
| EBITDA | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -91 | -42 | -77 | -63 | -152 | -73 | 2 | -94 | -127 |
| Operating Margin | -293.55% | -120% | -105.48% | -315% | -760% | -730% | 2.15% | -78.33% | - |
| Earnings before Tax (EBT) 1 | -119 | -45 | -89 | -63 | -152 | -73 | 2 | -94 | -127 |
| Net income 1 | -119 | -45 | -90 | -63 | -153 | -73 | 2 | -95 | -127 |
| Net margin | -383.87% | -128.57% | -123.29% | -315% | -765% | -730% | 2.15% | -79.17% | - |
| EPS 2 | -11.78 | -3.260 | - | -5.000 | -12.10 | -5.730 | 0.1700 | -7.500 | -10.00 |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/11/21 | 2/14/22 | 5/12/22 | 8/10/22 | 11/10/22 | 2/9/23 | 8/10/23 | 11/9/23 | 2/8/24 |
1JPY in Million2JPY
Estimates
Balance Sheet Analysis
| Fiscal Period: Marzo | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | 600 | 550 | 2,187 | 1,903 | 1,670 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | - | - | -150 | -160 | -137 |
| ROE (net income / shareholders' equity) | - | -16.9% | -18.4% | -16.5% | -14.9% |
| ROA (Net income/ Total Assets) | - | -5.11% | -7.53% | -8.86% | -7.22% |
| Assets 1 | - | 1,956 | 3,374 | 3,781 | 3,573 |
| Book Value Per Share 2 | 63.20 | 57.10 | 173.0 | 147.0 | 126.0 |
| Cash Flow per Share 2 | 99.80 | 104.0 | 188.0 | 174.0 | 159.0 |
| Capex | - | - | 1 | 2 | 1 |
| Capex / Sales | - | - | 0.72% | 2% | 0.52% |
| Announcement Date | 8/18/21 | 8/18/21 | 6/30/22 | 6/30/23 | 6/28/24 |
1JPY in Million2JPY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -20.05% | 27.94M | |
| +63.05% | 856B | |
| +39.42% | 631B | |
| -4.78% | 359B | |
| +17.52% | 325B | |
| +8.43% | 297B | |
| +14.19% | 244B | |
| +5.81% | 234B | |
| +16.77% | 226B | |
| +14.63% | 177B |
- Stock Market
- Equities
- 4889 Stock
- Financials Renascience Inc.
